company background image
HYL logo

Hyloris Pharmaceuticals ENXTBR:HYL Stock Report

Last Price

€11.70

Market Cap

€327.6m

7D

0%

1Y

5.9%

Updated

12 Jul, 2024

Data

Company Financials +

Hyloris Pharmaceuticals SA

ENXTBR:HYL Stock Report

Market Cap: €327.6m

HYL Stock Overview

Engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas.

HYL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Hyloris Pharmaceuticals SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hyloris Pharmaceuticals
Historical stock prices
Current Share Price€11.70
52 Week High€14.10
52 Week Low€10.60
Beta0.56
11 Month Change0%
3 Month Change-4.10%
1 Year Change5.88%
33 Year Change-14.91%
5 Year Changen/a
Change since IPO12.61%

Recent News & Updates

Recent updates

Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Dec 28
Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Mar 08
Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Shareholder Returns

HYLBE PharmaceuticalsBE Market
7D0%2.0%1.8%
1Y5.9%26.2%5.8%

Return vs Industry: HYL underperformed the Belgian Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: HYL matched the Belgian Market which returned 5.1% over the past year.

Price Volatility

Is HYL's price volatile compared to industry and market?
HYL volatility
HYL Average Weekly Movement1.2%
Pharmaceuticals Industry Average Movement4.8%
Market Average Movement3.6%
10% most volatile stocks in BE Market6.5%
10% least volatile stocks in BE Market2.4%

Stable Share Price: HYL has not had significant price volatility in the past 3 months.

Volatility Over Time: HYL's weekly volatility (1%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201242Stijn Van Rompayhyloris.com

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer.

Hyloris Pharmaceuticals SA Fundamentals Summary

How do Hyloris Pharmaceuticals's earnings and revenue compare to its market cap?
HYL fundamental statistics
Market cap€327.60m
Earnings (TTM)-€15.76m
Revenue (TTM)€2.81m

116.4x

P/S Ratio

-20.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HYL income statement (TTM)
Revenue€2.81m
Cost of Revenue€93.00k
Gross Profit€2.72m
Other Expenses€18.48m
Earnings-€15.76m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Sep 05, 2024

Earnings per share (EPS)-0.56
Gross Margin96.70%
Net Profit Margin-560.13%
Debt/Equity Ratio0%

How did HYL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.